These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 39218023)

  • 1. Structural Basis for Evasion of New SARS-CoV-2 Variants from the Potent Virus-Neutralizing Nanobody Targeting the S-Protein Receptor-Binding Domain.
    Sluchanko NN; Shcheblyakov DV; Varfolomeeva LA; Favorskaya IA; Dolzhikova IV; Korobkova AI; Alekseeva IA; Esmagambetov IB; Derkaev AA; Prokofiev VV; Zorkov ID; Logunov DY; Gintsburg AL; Popov VO; Boyko KM
    Biochemistry (Mosc); 2024 Jul; 89(7):1260-1272. PubMed ID: 39218023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.
    Graham C; Seow J; Huettner I; Khan H; Kouphou N; Acors S; Winstone H; Pickering S; Galao RP; Dupont L; Lista MJ; Jimenez-Guardeño JM; Laing AG; Wu Y; Joseph M; Muir L; van Gils MJ; Ng WM; Duyvesteyn HME; Zhao Y; Bowden TA; Shankar-Hari M; Rosa A; Cherepanov P; McCoy LE; Hayday AC; Neil SJD; Malim MH; Doores KJ
    Immunity; 2021 Jun; 54(6):1276-1289.e6. PubMed ID: 33836142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AlphaFold2 Modeling and Molecular Dynamics Simulations of the Conformational Ensembles for the SARS-CoV-2 Spike Omicron JN.1, KP.2 and KP.3 Variants: Mutational Profiling of Binding Energetics Reveals Epistatic Drivers of the ACE2 Affinity and Escape Hotspots of Antibody Resistance.
    Raisinghani N; Alshahrani M; Gupta G; Verkhivker G
    Viruses; 2024 Sep; 16(9):. PubMed ID: 39339934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2.
    Cornish K; Huo J; Jones L; Sharma P; Thrush JW; Abdelkarim S; Kipar A; Ramadurai S; Weckener M; Mikolajek H; Liu S; Buckle I; Bentley E; Kirby A; Han X; Laidlaw SM; Hill M; Eyssen L; Norman C; Le Bas A; Clarke J; James W; Stewart JP; Carroll M; Naismith JH; Owens RJ
    Open Biol; 2024 Jun; 14(6):230252. PubMed ID: 38835241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies.
    Cerutti G; Rapp M; Guo Y; Bahna F; Bimela J; Reddem ER; Yu J; Wang P; Liu L; Huang Y; Ho DD; Kwong PD; Sheng Z; Shapiro L
    Structure; 2021 Jul; 29(7):655-663.e4. PubMed ID: 34111408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced potency of an IgM-like nanobody targeting conserved epitope in SARS-CoV-2 spike N-terminal domain.
    Liu B; Liu H; Han P; Wang X; Wang C; Yan X; Lei W; Xu K; Zhou J; Qi J; Fan R; Wu G; Tian WX; Gao GF; Wang Q
    Signal Transduct Target Ther; 2024 May; 9(1):131. PubMed ID: 38740785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
    Cao Y; Wang J; Jian F; Xiao T; Song W; Yisimayi A; Huang W; Li Q; Wang P; An R; Wang J; Wang Y; Niu X; Yang S; Liang H; Sun H; Li T; Yu Y; Cui Q; Liu S; Yang X; Du S; Zhang Z; Hao X; Shao F; Jin R; Wang X; Xiao J; Wang Y; Xie XS
    Nature; 2022 Feb; 602(7898):657-663. PubMed ID: 35016194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape.
    Koenig PA; Das H; Liu H; Kümmerer BM; Gohr FN; Jenster LM; Schiffelers LDJ; Tesfamariam YM; Uchima M; Wuerth JD; Gatterdam K; Ruetalo N; Christensen MH; Fandrey CI; Normann S; Tödtmann JMP; Pritzl S; Hanke L; Boos J; Yuan M; Zhu X; Schmid-Burgk JL; Kato H; Schindler M; Wilson IA; Geyer M; Ludwig KU; Hällberg BM; Wu NC; Schmidt FI
    Science; 2021 Feb; 371(6530):. PubMed ID: 33436526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion.
    Xue S; Han Y; Wu F; Wang Q
    Protein Cell; 2024 May; 15(6):403-418. PubMed ID: 38442025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex.
    Mannar D; Saville JW; Zhu X; Srivastava SS; Berezuk AM; Tuttle KS; Marquez AC; Sekirov I; Subramaniam S
    Science; 2022 Feb; 375(6582):760-764. PubMed ID: 35050643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
    Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R
    Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
    Huo J; Le Bas A; Ruza RR; Duyvesteyn HME; Mikolajek H; Malinauskas T; Tan TK; Rijal P; Dumoux M; Ward PN; Ren J; Zhou D; Harrison PJ; Weckener M; Clare DK; Vogirala VK; Radecke J; Moynié L; Zhao Y; Gilbert-Jaramillo J; Knight ML; Tree JA; Buttigieg KR; Coombes N; Elmore MJ; Carroll MW; Carrique L; Shah PNM; James W; Townsend AR; Stuart DI; Owens RJ; Naismith JH
    Nat Struct Mol Biol; 2020 Sep; 27(9):846-854. PubMed ID: 32661423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
    Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
    Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for the evolution and antibody evasion of SARS-CoV-2 BA.2.86 and JN.1 subvariants.
    Yang H; Guo H; Wang A; Cao L; Fan Q; Jiang J; Wang M; Lin L; Ge X; Wang H; Zhang R; Liao M; Yan R; Ju B; Zhang Z
    Nat Commun; 2024 Sep; 15(1):7715. PubMed ID: 39231977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape.
    Yang L; Li J; Guo S; Hou C; Liao C; Shi L; Ma X; Jiang S; Zheng B; Fang Y; Ye L; He X
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes.
    Sun D; Sang Z; Kim YJ; Xiang Y; Cohen T; Belford AK; Huet A; Conway JF; Sun J; Taylor DJ; Schneidman-Duhovny D; Zhang C; Huang W; Shi Y
    Nat Commun; 2021 Aug; 12(1):4676. PubMed ID: 34344900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies.
    Wang WB; Liang Y; Jin YQ; Zhang J; Su JG; Li QM
    J Mol Graph Model; 2021 Dec; 109():108035. PubMed ID: 34562851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.